Today: 14 March 2026
Subscribe
Browse Category

NASDAQ:ASBP 11 November 2025 - 15 December 2025

Aspire Biopharma Holdings (ASBP) Stock on Dec. 15, 2025: Nasdaq Extension, FDA Pre‑IND Momentum, and Dilution Risks Investors Are Watching

Aspire Biopharma Holdings (ASBP) Stock on Dec. 15, 2025: Nasdaq Extension, FDA Pre‑IND Momentum, and Dilution Risks Investors Are Watching

Aspire Biopharma shares fell about 8% to $0.095 on December 15, 2025, as the company’s stock transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market. Aspire faces Nasdaq deadlines to regain compliance with minimum bid price and equity rules by early 2026. The company is also advancing an FDA regulatory milestone for its sublingual aspirin program.
15 December 2025
·
Aspire Biopharma (ASBP) Jumps on $100M Equity Line and Q3 Filing – What Matters on November 14, 2025

Aspire Biopharma (ASBP) Jumps on $100M Equity Line and Q3 Filing – What Matters on November 14, 2025

Aspire Biopharma Holdings (NASDAQ: ASBP) surged over 30% in pre-market trading Friday after announcing a new $100 million equity line of credit with Arena Business Solutions and releasing its Q3 2025 10-Q. Shares traded around $0.14, up from Thursday’s $0.11 close, with market cap near $5.3 million. The new deal replaces a prior ELOC signed in February.
14 November 2025
·
Aspire Biopharma (ASBP) Whipsaws on Heavy Volume Today as Investors Eye Reverse‑Split Authority and Nasdaq Compliance — Nov. 11, 2025

Aspire Biopharma (ASBP) Whipsaws on Heavy Volume Today as Investors Eye Reverse‑Split Authority and Nasdaq Compliance — Nov. 11, 2025

ASBP shares dropped roughly 20–25% mid-session Nov. 11, trading on heavy volume and swinging between $0.1189 and $0.2471. No new company news was released; the last updates were last week’s CPHI Frankfurt partnering recap and special meeting results. Nasdaq delisting risk remains after Aspire requested a hearing to contest compliance failures.
11 November 2025
·

Stock Market Today

  • Dell Technologies Seen Undervalued Despite Recent Share Price Surge
    March 13, 2026, 10:46 PM EDT. Dell Technologies (DELL) shares have jumped 61.4% over the past year and 332.1% over three years, raising questions about valuation. Despite this strong momentum, a Discounted Cash Flow (DCF) analysis estimates Dell's intrinsic value at around $248.92 per share, suggesting the stock trades at a 39.1% discount to fair value based on projected free cash flows. The model projects free cash flow growing from $8.12 billion currently to $11.65 billion by 2031. This valuation indicates Dell remains undervalued amid broader investor focus on capital spending by enterprise and cloud customers influencing demand for PCs, servers, and storage hardware. Dell scores 5 out of 6 on valuation metrics, supporting the case for investor interest despite recent gains.
Go toTop